Related references
Note: Only part of the references are listed.Prognostic impact of immunohistochemical biomarkers in diffuse large B-cell lymphoma in the rituximab era
Ritsuko Seki et al.
CANCER SCIENCE (2009)
Loss of HLA-DR expression and immunoblastic morphology predict adverse outcome in diffuse large B-cell lymphoma - analyses of cases from two prospective randomized clinical trials
Heinz-Wolfram Bernd et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2009)
被撤回的出版物: Immunohistochemical prognostic markers in diffuse large B-cell lymphoma: validation of tissue microarray as a prerequisite for broad clinical applications (a study from the Lunenburg Lymphoma Biomarker Consortium) (Retracted article. See vol. 65, pg. 861, 2012)
D. de Jong et al.
JOURNAL OF CLINICAL PATHOLOGY (2009)
Mutations of multiple genes cause deregulation of NF-κB in diffuse large B-cell lymphoma
Mara Compagno et al.
NATURE (2009)
Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma
Kai Fu et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Phase II study of dose-adjusted EPOCH and rituximab in untreated diffuse large B-Cell lymphoma with analysis of germinal center and post-germinal center biomarkers
Wyndham H. Wilson et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
LMO2 protein expression predicts survival in patients with diffuse large B-Cell lymphoma treated with anthracycline-based chemotherapy with and without rituximab
Yasodha Natkunam et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas:: a randomised controlled trial (RICOVER-60)
Michael Pfreundschuh et al.
LANCET ONCOLOGY (2008)
Stromal Gene Signatures in Large-B-Cell Lymphomas
G. Lenz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Oncogenic CARD11 mutations in human diffuse large B cell lymphoma
Georg Lenz et al.
SCIENCE (2008)
Profiling of diffuse large B-cell lymphoma by immunohistochemistry:: identification of prognostic subgroups
Lene Dissing Sjo et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2007)
Absence of cyclin-D2 and Bcl-2 expression within the germinal centre type of diffuse large B-cell lymphoma identifies a very good prognostic subgroup of patients
F. Amen et al.
HISTOPATHOLOGY (2007)
Prognostic impact of immunohistochemically defined germinal center phenotype in diffuse large B-cell lymphoma patients treated with immunochemotherapy
Heidi Nyman et al.
BLOOD (2007)
Respective prognostic values of germinal center phenotype and early 18fluorodeoxyglucose-positron emission tomography scanning in previously untreated patients with diffuse large B-cell lymphoma
Jehan Dupuis et al.
HAEMATOLOGICA (2007)
Immunophenotype as prognostic factor for diffuse large B-cell lymphoma in patients undergoing clinical risk-adapted therapy
H. Veelken et al.
ANNALS OF ONCOLOGY (2007)
Immunohistochemical prognostic markers in diffuse large B-cell lymphoma: Validation of tissue microarray as a prerequisite for broad clinical applications - A study from the Lunenburg Lymphoma Biomarker Consortium
Daphne de Jong et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Prognostic impact of germinal center-associated proteins and chromosomal breakpoints in poor-risk diffuse large B-cell lymphoma
Gustaaf W. van Imhoff et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Prognostic significance of Bcl-6 protein expression in DLBCL treated with CHOP or R-CHOP: a prospective correlative study
Jane N. Winter et al.
BLOOD (2006)
Immunohistochemical profiling based on Bcl-2, CD10 and MUMI expression improves risk stratification in patients with primary nodal diffuse large B cell lymphoma
JJF Muris et al.
JOURNAL OF PATHOLOGY (2006)
Diffuse large B-cell lymphoma subgroups have distinct genetic profiles that influence tumor biology and improve gene-expression-based survival prediction
S Bea et al.
BLOOD (2005)
Large cleaved and immunoblastic lymphoma may represent two distinct clinicopathologic entities within the group of diffuse large B-cell lymphomas
P De Paepe et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Evaluation of immunophenotype in diffuse large B-cell lymphoma and its impact on prognosis
M Berglund et al.
MODERN PATHOLOGY (2005)
Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response
S Monti et al.
BLOOD (2005)
Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray
CP Hans et al.
BLOOD (2004)
Rituximab plus CHOP (R-CHOP) overcomes bcl-2-associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL)
N Mounier et al.
BLOOD (2003)
Clinical impact of the differentiation profile assessed by immunophenotyping in patients with diffuse large B-cell lymphoma
L Colomo et al.
BLOOD (2003)
The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma
A Rosenwald et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Diffuse large B-cell lymphoma: A clinicopathologic analysis of 444 cases classified according to the updated Kiel classification
J Diebold et al.
LEUKEMIA & LYMPHOMA (2002)
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
AA Alizadeh et al.
NATURE (2000)
Share Paper
